Phosphodiesterase type 5 inhibitors: Discovery and therapeutic utility

Drugs of the Future

Volumn 26, Issue 2, 2001, Pages 153-162

  Rotella, D P ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPENTYL 3 ETHYL 6 (3 ETHOXY 4 PYRIDYL) 1H PYRAZOLO[3,4 D]PYRIMIDIN 4 ONE; 2 (4 AMINOPHENYL) 1,2 DIHYDRO 1 OXO 7 (2 PYRIDINYLMETHOXY) 4 (3,4,5 TRIMETHOXYPHENYL) 3 ISOQUINOLINECARBOXYLIC ACID METHYL ESTER; E 4010; ISOQUINOLINE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PHTHALAZINE DERIVATIVE; PYRAZOLOPYRIMIDINE DERIVATIVE; SILDENAFIL; TADALAFIL; UK 122764; UNCLASSIFIED DRUG; VARDENAFIL; WIN 65579; ZAPRINAST;

ANTIHYPERTENSIVE ACTIVITY; DRUG SYNTHESIS; ERECTILE DYSFUNCTION; HUMAN; HYPERTENSION; NONHUMAN; PENIS ERECTION; REVIEW; STRUCTURE ACTIVITY RELATION; VASODILATATION;

EID: 0035061248     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2001.026.02.658842     Document Type: Review

References (44)

1. NIH consensus conference: Impotence
2. The epidemiology of erectile dysfunction
3. Impotence and its medical and psychological correlates: Results of the Massachusetts Male Aging Study
4. Impotence - The most neglected complication of diabetes
5. Erectile dysfunction
6. Sildenafil: A new oral therapy of erectile dysfunction
7. Cyclic GMP phosphodiesterase 5: Target of sildenafil
8. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms
9. Characterization of a novel cGMP binding protein from rat lung
10. The structure of a bovine lung cGMP-binding, cGMP-specific phosphodiesterase deduced from a cDNA clone
11. Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene
12. Isolation and characterization of cDNAs encoding PDE5a, a human cGMP binding, cGMP specific 3′,5′-cyclic nucleotide phosphodiesterase
13. Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile tissue
14. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase 5 by sildenafil and related compounds
15. Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells
16. Hydropathic analysis and mutagenesis of the catalytic domain of the cGMP-binding and cGMP-specific phosphodiesterase 5. cGMP versus cAMP substrate selectivity
17. Sildenafil (Viagra™), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction
18. Synthesis and cyclic GMP phosphodiesterase inhibitory activity of a series of 6-phenylpyrazolo[3,4-d]pyrimidinones
19. Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity
20. Synthesis and evaluation of potent and selective c-GMP phosphodiesterase inhibitors
21. Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors
22. 4-Benzylamino-1-chloro-6-substituted phthalazines: Synthesis and inhibitory activity toward phosphodiesterase 5
23. Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity
24. 4-(3-Chloro-4-methoxybenzyl)amino phthalazines: Synthesis and inhibitory activity toward phosphodiesterase 5
25. Novel selective PDEIV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans
26. 1-Arylnaphthalene lignan: A novel scaffold for type 5 phosphodiesterase inhibitor
27. N-3-Substituted imidazoquinazolinones: Potent and selective PDE5 inhibitors as potential agents for the treatment of erectile dysfunction
28. Optimization of substituted N-3-benzyl imidazoquinazolinone sulfonamides as potent and selective PDE5 inhibitors
29. Potentiation of penile tumescence by T-1032, a new potent and specific phosphodiesterase type V inhibitor
30. Vardenafil, a new PDE5 inhibitor, increases cGMP in rabbit corpus cavernosum
31. A conscious-rabbit model is able to demonstrate the efficacy of vardenafil and sildenafil on penile erection
32. Efficacy and safety of IC351 treatment for erectile dysfunction
33. On-demand treatment of ED with IC351
34. Daily IC351 treatment of ED
35. Cardiovascular activity of WIN 65579, a novel inhibitor of cyclic GMP phosphodiesterase 5
36. Experimental studies on guanosine 3′,5′-cyclic monophosphate levels and airway responsiveness of the novel PDE5 inhibitor SR265579 in guinea pigs
37. Improvement of mortality by long term E4010 treatment in monocrotaline induced pulmonary hypertensive rats
38. Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy